Tgf Alpha Stimulant
Tgf Alpha Stimulant - Related Videos
09:18
Spheroid Assay to Measure TGF-β-induced Invasion
0 Views •
Cited by 41 •
2011
An assay to quantitatively measure Transforming Growth Factor (TGF)-β-induced invasion in 3-dimensional collagen gels is described. This assay takes advantage of the MCF10A series of cell lines, which represent different stages of breast cancer development. This method can be adopted to be used with other cell lines and might be used to investigate other potential activators or inhibitors of invasion.
01:16
TGF - β Signaling Pathway
0 Views •
2023
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
11:02
Combining Transcranial Magnetic Stimulation and fMRI to Examine the Default Mode Network
0 Views •
Cited by 17 •
2010
In this article, we examine the methodology and considerations relevant to the combination of TMS and fMRI to examine the effects of brain stimulation on the default network.
01:30
Detection of Phosphorylated Alpha-Synuclein Using Western Blotting
0 Views •
2025
Add a loading buffer containing a detergent, a reducing agent, and a tracking dye.
03:25
Immunostaining of Neurons Treated with Alpha-Synuclein Aggregates
0 Views •
2025
This video demonstrates the immunostaining of neurons treated with alpha-synuclein (αS) aggregates. The neurons are first treated with αS aggregates. They are then fixed, permeabilized, and treated with a blocking solution. Primary antibodies are added, followed by a fluorescently labeled secondary antibodies and a nuclear stain. The sample is then mounted and observed under a microscope.
FAQs
The key event is TGF-alpha binding to EGFR, followed by receptor dimerization and autophosphorylation. These phosphorylation events activate intracellular signaling routes, including MAPK and PI3K-AKT. In experimental cancer systems, this sequence connects an external growth-factor signal with cellular programs that support proliferation and survival, allowing investigators to examine EGFR-dependent tumor behavior.
MAPK and PI3K-AKT represent distinct downstream signaling routes activated after EGFR stimulation. Their involvement helps explain how the receptor signal can produce both growth-related and survival-related effects. Examining these pathways gives cancer researchers a mechanistic framework for interpreting responses to TGF-alpha stimulation and for relating altered signaling to tumor progression.
A TGF-alpha stimulant increases the growth-factor signal delivered through EGFR, whereas an EGFR-blocking approach is intended to interrupt aberrant signaling from that receptor. Using these contrasting experimental conditions helps researchers distinguish effects associated with pathway activation from effects produced when signaling is suppressed, supporting studies of receptor dependence and therapeutic response.
Researchers can incorporate the stimulant into experimental systems designed to reproduce growth-factor-driven tumor behavior. The resulting EGFR-dependent response can be examined in relation to cellular proliferation, survival, and altered signaling. This approach provides a controlled way to investigate how increased TGF-alpha activity may contribute to tumor progression without treating pathway activation as an isolated molecular event.
This approach is useful when investigators need to study how cancer cells respond to increased growth-factor signaling or determine whether observed behavior depends on EGFR activity. It supports research into tumor progression by connecting altered signaling with proliferation and survival, while also providing a model system for evaluating the consequences of pathway activation.
Stimulated experimental systems can help researchers test therapies designed to block aberrant EGFR signaling. By examining responses under conditions of increased TGF-alpha-driven activity, investigators can assess how effectively a treatment counters receptor-associated signaling and its growth-related consequences. These models therefore connect mechanistic cancer biology with the development and testing of pathway-directed interventions.